KemPharm, Inc. (KMPH): Price and Financial Metrics


KemPharm, Inc. (KMPH): $6.10

0.06 (+0.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KMPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KMPH POWR Grades

  • KMPH scores best on the Quality dimension, with a Quality rank ahead of 68.39% of US stocks.
  • The strongest trend for KMPH is in Growth, which has been heading down over the past 179 days.
  • KMPH ranks lowest in Growth; there it ranks in the 2nd percentile.

KMPH Stock Summary

  • With a price/sales ratio of 21.94, KEMPHARM INC has a higher such ratio than 94.44% of stocks in our set.
  • With a year-over-year growth in debt of 717.72%, KEMPHARM INC's debt growth rate surpasses 97.2% of about US stocks.
  • As for revenue growth, note that KMPH's revenue has grown -65.44% over the past 12 months; that beats the revenue growth of only 2.44% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to KEMPHARM INC, a group of peers worth examining would be IPA, CDE, ABEO, SESN, and GORO.
  • Visit KMPH's SEC page to see the company's official filings. To visit the company's web site, go to kempharm.com.

KMPH Valuation Summary

  • KMPH's price/earnings ratio is -6.6; this is 133.67% lower than that of the median Healthcare stock.
  • KMPH's EV/EBIT ratio has moved up 1 over the prior 91 months.

Below are key valuation metrics over time for KMPH.

Stock Date P/S P/B P/E EV/EBIT
KMPH 2022-09-23 20.5 2.0 -6.6 -4.5
KMPH 2022-09-22 20.9 2.1 -6.8 -4.6
KMPH 2022-09-21 21.2 2.1 -6.8 -4.7
KMPH 2022-09-20 21.8 2.2 -7.0 -4.9
KMPH 2022-09-19 22.2 2.2 -7.2 -5.1
KMPH 2022-09-16 22.8 2.3 -7.4 -5.3

KMPH Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 118.64%.
  • Its 4 year net income to common stockholders growth rate is now at -8.89%.
  • The 5 year net income to common stockholders growth rate now stands at -8.89%.
Over the past 67 months, KMPH's revenue has gone up $9,812,000.

The table below shows KMPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 9.812 -11.235 -30.368
2022-03-31 20.498 9.54 -17.021
2021-12-31 28.65 10.439 -62.897
2021-09-30 28.434 10.228 -65.05
2021-06-30 28.394 11.907 -66.3
2021-03-31 23.316 -2.503 -54.746

KMPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KMPH has a Quality Grade of B, ranking ahead of 90.29% of graded US stocks.
  • KMPH's asset turnover comes in at 0.451 -- ranking 100th of 682 Pharmaceutical Products stocks.
  • NAII, ACUR, and EGRX are the stocks whose asset turnover ratios are most correlated with KMPH.

The table below shows KMPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.451 1.000 -0.427
2021-03-31 0.745 1.000 -0.609
2020-12-31 1.218 1.000 -0.410
2020-09-30 1.146 1.081 -0.400
2020-06-30 1.958 1.000 -0.069
2020-03-31 1.318 1.000 -0.222

KMPH Price Target

For more insight on analysts targets of KMPH, see our KMPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.00 Average Broker Recommendation 1.75 (Moderate Buy)

KMPH Stock Price Chart Interactive Chart >

Price chart for KMPH

KMPH Price/Volume Stats

Current price $6.10 52-week high $10.80
Prev. close $6.04 52-week low $4.00
Day low $5.91 Volume 125,300
Day high $6.15 Avg. volume 408,176
50-day MA $5.91 Dividend yield N/A
200-day MA $5.68 Market Cap 210.41M

KemPharm, Inc. (KMPH) Company Bio


KemPharm Inc. provides biopharmaceutical services. The Company offers discovery and development of therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular diseases.


KMPH Latest News Stream


Event/Time News Detail
Loading, please wait...

KMPH Latest Social Stream


Loading social stream, please wait...

View Full KMPH Social Stream

Latest KMPH News From Around the Web

Below are the latest news stories about KEMPHARM INC that investors may wish to consider to help them evaluate KMPH as an investment opportunity.

KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study

KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.

Yahoo | September 29, 2022

KemPharm's Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder

KemPharm Inc (NASDAQ: KMPH) announced topline data from its exploratory Phase 1 trial confirming the relative cardiovascular effects and pharmacokinetics of serdexmethylphenidate (SDX) compared to Ritalin (racemic methylphenidate), a commonly prescribed CNS stimulant. SDX, KemPharm's proprietary prodrug of d-methylphenidate (d-MPH), is the sole active pharmaceutical ingredient (API) in KP1077, a potential treatment for idiopathic hypersomnia (IH), a rare sleep disorder. Based on the data, KemPha

Yahoo | September 28, 2022

KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced topline data from its exploratory Phase 1 clinical trial confirming the relative cardiovascula

Yahoo | September 28, 2022

Health Check: How Prudently Does KemPharm (NASDAQ:KMPH) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | September 7, 2022

KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference being

Yahoo | September 1, 2022

Read More 'KMPH' Stories Here

KMPH Price Returns

1-mo 7.96%
3-mo 26.82%
6-mo 27.88%
1-year -31.07%
3-year -46.30%
5-year -89.90%
YTD -29.97%
2021 -22.23%
2020 84.55%
2019 -78.69%
2018 -56.05%
2017 37.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6301 seconds.